Showing results (71-80 of 79) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
British Journal of Cancer|July 15, 2010
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label studyL R Molife, P C Fong, L Paccagnella, et al.British Journal of Cancer|January 28, 2010
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancerA H M Reid, G Attard, L Ambroisine, et al.British Journal of Cancer|April 12, 2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumoursT A Yap, H Cortes-Funes, H Shaw, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 15, 2020
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancerS Halabi, S Dutta, C M Tangen, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2020
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancerM P Kolinsky, P Rescigno, D Bianchini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study groupK Fizazi, S Tjulandin, R Salvioni, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2018
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancerB Basu, M G Krebs, R Sundar, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2018
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolM R Sydes, M R Spears, M D Mason, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 5, 2015
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015S Gillessen, A Omlin, G Attard, et al.Pageof 8